Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.40 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.40 |
| ▸ | TRPV3 | Q8NET8 | 7/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | XDH | P47989 | 2/20 | 0.37 |
| ▸ | PPARD | Q03181 | 2/20 | 0.37 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL832657 | 0.90 | XDH (0.42) | SCN8ASCN10ATRPV3ADORA3XDH | |
| SCHEMBL832414 | 0.86 | ADORA3 (0.41) | TRPV3ADORA3PPARD | |
| SCHEMBL831714 | 0.75 | MCL1 (0.40) | TRPV3ADORA3PPARDLTB4R | |
| SCHEMBL830689 | 0.73 | MAPT (0.44) | ADORA3KDM4E | |
| SCHEMBL831311 | 0.72 | MAPT (0.43) | ADORA3KDM4E | |
| SCHEMBL831844 | 0.71 | ALDH1A1 (0.42) | ADORA3XDHPPARDLTB4RKDM4E | |
| SCHEMBL26074168 | 0.70 | PLA2G2A (0.60) | KDM4EKMT2A | |
| SCHEMBL830293 | 0.68 | ADORA3 (0.41) | ADORA3KMT2A | |
| SCHEMBL831416 | 0.68 | MAPT (0.43) | ADORA3KDM4E | |
| SCHEMBL829500 | 0.67 | ALDH1A1 (0.48) | ADORA3KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143411-B2 | Substituted 6-phenylnicotinic acids and their use | BAYER ANIMAL HEALTH GMBH (DE) | 2012-03-27 | — | — | US | disclosed |
| US-8143411-B2 | Substituted 6-phenylnicotinic acids and their use | BAYER ANIMAL HEALTH GMBH (DE) | 2012-03-27 | — | — | US | disclosed |
| US-8143411-B2 | Substituted 6-phenylnicotinic acids and their use | BAYER ANIMAL HEALTH GMBH (DE) | 2012-03-27 | — | — | US | disclosed |
| US-20100234432-A1 | Substituted 6-phenylnicotinic acids and their use | BAYER ANIMAL HEALTH GMBH (DE) | 2010-09-16 | — | — | US | disclosed |
| US-20100234432-A1 | Substituted 6-phenylnicotinic acids and their use | BAYER ANIMAL HEALTH GMBH (DE) | 2010-09-16 | — | — | US | disclosed |
| US-20100234432-A1 | Substituted 6-phenylnicotinic acids and their use | BAYER ANIMAL HEALTH GMBH (DE) | 2010-09-16 | — | — | US | disclosed |
| WO-2009033561-A1 | SUBSTITUTED 6-PHEYLNICOTINIC ACIDS AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234432-A1 | Substituted 6-phenylnicotinic acids and their use | SLC5A6, FABP3, NAPRT | SCN8A 2574/4885SCN10A 2241/4885TRPV3 4035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.